Quick links
The combination of superior sensitivity and specificity and fast kinetics is what sets PCT apart from other biomarkers when assessing bacterial infection and its severity. But not all PCT tests are the same; it’s important to know how to identify a PCT assay that sustains improvement of patient care through proven clinical, economic, and analytical performance. Only B·R·A·H·M·S PCTTM assays offer a substantial amount of clinical evidence and alignment to a gold standard, ensuring continuous clinical performance.1, 2
PCT has been extensively documented in over 10,000 publications3, including reviews, clinical trials, meta-analyses, experts’ consensus4 and international and national guidelines. Almost all this evidence has been generated using Thermo ScientificTM B·R·A·H·M·S PCTTM assays.
This strong evidence from reproducible, randomized clinical trials supports the effectiveness and safety of PCT-aided antibiotic stewardship protocols, for which only B·R·A·H·M·S PCT has an approved indication.
Furthermore, the clinical value of B·R·A·H·M·S PCT has been recognized in antibiotic stewardship guidelines issued by IDSA (Infectious Disease Society of America) and the SSC (Surviving Sepsis Campaign*), as well as by the WHO (World Health Organization), which included procalcitonin in its Essential Diagnostics List (EDL). B·R·A·H·M·S PCT is included in many national clinical guidelines and recommendations related to the management of bacterial infection and sepsis.
*The Surviving Sepsis Campaign (SSC) is a joint collaboration of the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM), committed to reducing mortality and morbidity from sepsis and septic shock worldwide.
Non-licensed assays are missing clinical performance data in many of the applications of procalcitonin.
B·R·A·H·M·S PCT-aided algorithms are used to help reduce antibiotic prescriptions, deescalate therapy when appropriate and tailor the therapy duration to individual patient needs. This reduction of antibiotic exposure can benefit in shortening hospital stays, lowering antibiotic resistance and improving outcomes. In addition to improving patient care, B·R·A·H·M·S PCT allows for significant savings in healthcare costs.
*ADE: Adverse Drug Event
PCT cut-offs and clinical algorithms were established using the global reference standard assay: B·R·A·H·M·S PCT Gold Standard.
Through alignment to a validated Gold Standard, B·R·A·H·M·S PCT assays ensure reliable clinical performance in multiple indications2, making them the safe choice for patient assessment.
With a high-quality PCT test, clinicians can:
When saving lives, quality is a necessity not to be compromised.
The three pillars of B·R·A·H·M·S PCT Gold Standard performance
Validation
B·R·A·H·M·S PCT diagnostic algorithms have undergone thorough clinical validation.5-10
B·R·A·H·M·S PCT algorithms are based on cut-off values5-10…
…or related to concentration changes from peak values.9,10
Alignment
A rigorous quality program monitors alignment of all B·R·A·H·M·S PCT assays to the B·R·A·H·M·S PCT Gold Standard.
Clinical performance
Through alignment to a validated standard, B·R·A·H·M·S PCT assays ensure clinical performance in all their applications.2
![]() |
![]() |
|
Clinical assessment on the presence, course, and severity of systemic bacterial infections, sepsis, and septic shock.5-7 | ![]() Systemic infections and sepsis |
Several studies have discouraged use of the same clinical cut-offs in non-B·R·A·H·M·S PCT assays.12,13
Discordance rates up to 25.5% have been reported in non-B·R·A·H·M·S PCT assays using the 0.5 μg/L systemic infection cut-off.12,13 |
Aid decision making on antibiotic therapy, for patients with suspected or confirmed lower respiratory tract infections (LRTI).8 | ![]() LRTI |
Low-range performance of some non-B·R·A·H·M·S PCT assays has been reported to hinder application of LRTI diagnostic algorithms.11-13 |
Aiding of antibiotic treatment decisions in sepsis9 and LRTI,8,14 with B·R·A·H·M·S PCT has been proven to reduce antibiotic use and mortality,15,16 and the incidence of any new infection or death attributed to Clostridioides difficile or multidrug-resistant organism infections.16 | ![]() Antibiotic stewardship |
When discussing antibiotic decisions, authors have concluded that: “use of these clinical decision limits in non-B·R·A·H·M·S-associated assays […] could lead to overdiagnosis or […] elongated and imprecise antibiotic therapy, which […] may contribute to the development of multi-resistant germs.”12 |
Serial testing of patient samples with B·R·A·H·M·S PCT assays to monitor patients’ response to antibiotic therapy has been validated in several studies.8,9,14 | ![]() Serial testing |
Faulty serial testing of non-licensed PCT assays has been observed to potentially lead to misdiagnosis and expose patients to associated risks.13 |
Thermo Fisher Scientific products are distributed globally. Uses, applications, and availability of products in each country depend on local regulatory marketing authorization status, please consult the Instructions For Use (IFU) available in your country.
All B·R·A·H·M·S PCT assays offer excellent correlation and concordance when using the established cut-offs and algorithms.1
![]() |
B·R·A·H·M·S PCT sensitive KRYPTOR | ![]() |
PATHFAST™ B·R·A·H·M·S PCT |
![]() |
ALINITY I B·R·A·H·M·S PCT ARCHITECT B·R·A·H·M·S PCT |
![]() |
VITROS® B·R·A·H·M·S PCT |
![]() |
VIDAS® B·R·A·H·M·S PCT | ![]() |
ELECSYS® B·R·A·H·M·S PCT |
![]() |
LIASON® B·R·A·H·M·S PCT II GEN | ADVIA Centaur® B·R·A·H·M·S PCT Attelica® IM B·R·A·H·M·S PCT Dimension® EXL™ LOCI® B·R·A·H·M·S PCT |
|
![]() |
Lumipulse® G B·R·A·H·M·S PCT | Not all intended uses and applications mentioned are registered for every product in every country. |
© 2024 Thermo Fisher Scientific Inc. All rights reserved. B·R·A·H·M·S PCT and all other trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. ADVIA Centaur, Atellica IM, Dimension EXL and LOCI are trademarks of Siemens Healthcare Diagnostics. ALINITY i and ARCHITECT are trademarks of Abbott Laboratories. Elecsys is a trademark of Roche Diagnostics. LIAISON is a trademark of DiaSorin S.p.A. Lumipulse is a trademark of Fujirebio Inc. PATHFAST is a trademark of LSI Medience Corporation. VIDAS is a trademark of bioMérieux S.A. VITROS is a trademark of Ortho Clinical Diagnostics. KRYPTOR is a trademark of CisBio International, licensed for use by B·R·A·H·M·S GmbH.
Patents: www.brahms.de/patents